Abstract:Cytomegalovirus (CMV) infection is one of the most common infections in humans, and CMV antigens are the major drivers of repetitive T-cell stimulation as a part of a well-adapted immune response in immunocompetent individuals. With higher age, the recurrent clonal expansion of CMV-specific T cells results in high frequencies of CMV-specific effector T cells. CMV seropositivity has also been linked to arterial stiffness and an increased risk of developing cardiovascular diseases (CVD). The RESIST Senior Individuals (SI) cohort is a population-based cohort with focus on the elderly, established to shed light on the age-related changes of the immune system and the accompanied reduced capability to fight infectious diseases. Here we investigated the frequency and phenotype of CMVpp65-specific CD8 T cells in the circulation of individuals of different age groups by means of MHC-I tetramer staining and their associations with age and associated factors such as serostatus and blood pressure. In the SI cohort, the frequency of CMV-specific T cells within the CD8 T cell fraction was increased with age, as previously reported. We add to previous knowledge by showing that this frequency is associated with the total percentage and absolute counts of CD8 and CD4 CD8 double-positive T cells within leukocytes. Systolic blood pressure (SBP) and history of CVD correlated with the frequency of CMV-specific CD8 T cells. Focusing on CMV-specific T cell subtypes, we show here that the frequencies of T and CD27-expressing T cells were associated with higher age. T and CD27 T cell frequencies were increased in donors with high CMV-IgG titers. Furthermore, SBP significantly correlated with CMV-specific effector CD8 T cells, which was mostly reflected by CD27 T cells. In conclusion, different effector T-cell subtypes were associated with age, serostatus and SBP, suggesting that it is not age that renders elderly CMV-positive individuals susceptible to CVD, but the immune response to CMV. Our study suggests that detailed immunophenotyping may identify individuals whose immune systems are strongly influenced by the response to CMV, leading to health consequences and impairing healthy aging.

Exploring Their Connection in the Context of Aging, Health, and Disease

Advances in cytomegalovirus (CMV) biology and its relationship to health, diseases, and aging

The Immune Response Against Human Cytomegalovirus Links Cellular to Systemic Senescence

Potential relationship between cytomegalovirus and immunosenescence: Evidence from observational studies

From aging to long COVID: exploring the convergence of immunosenescence, inflammaging, and autoimmunity

Relation of CMV and brain atrophy to trajectories of immunosenescence in diverse populations

Inflammaging, immunosenescence, and cardiovascular aging: insights into long COVID implications

Aging brain: exploring the interplay between bone marrow aging, immunosenescence, and neuroinflammation

The Impact of Immune System Aging on Infectious Diseases

Aging, inflammaging and immunosenescence as risk factors of severe COVID-19

Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19

Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients

Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?

A human circulating immune cell landscape in aging and COVID-19

T cell responses to cytomegalovirus

Different CMV-specific effector T cell subtypes are associated with age, CMV serostatus, and increased systolic blood pressure

Anti-cytomegalovirus antibody levels stratify human immune profiles across the lifespan

Modulation of Host Immune Defenses by Cytomegalovirus: Advanced Insights from Evolutionary Game Theory

SARS-CoV-2 infection represents a high risk for the elderly: analysis of pathogenesis

Aging mitochondria in the context of SARS-CoV-2: exploring interactions and implications

Cytomegalovirus as an Uninvited Guest in the Response to Vaccines in People Living with HIV